Identification of Immune Cell Components in Breast Tissues by a Multiparametric Flow Cytometry Approach.
TILs
breast cancer
deep flow cytometry
tumor microenvironment
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
10 Aug 2022
10 Aug 2022
Historique:
received:
30
06
2022
revised:
03
08
2022
accepted:
09
08
2022
entrez:
26
8
2022
pubmed:
27
8
2022
medline:
27
8
2022
Statut:
epublish
Résumé
Immune cell components are able to infiltrate tumor tissues, and different reports described the presence of infiltrating immune cells (TILs) in several types of solid tumors, including breast cancer. The primary immune cell component cells are reported as a lymphocyte population mainly comprising the cytotoxic (CD8+) T cells, with varying proportions of helper (CD4+) T cells and CD19+ B cells, and rarely NK cells. In clinical practice, an expert pathologist commonly detects TILs areas in hematoxylin and eosin (H&E)-stained histological slides via light microscopy. Moreover, other more in-depth approaches could be used to better define the immunological component associated with tumor tissues. Using a multiparametric flow cytometry approach, we have studied the immune cells obtained from breast tumor tissues compared to benign breast pathologies. A detailed evaluation of immune cell components was performed on 15 and 14 biopsies obtained from breast cancer and fibroadenoma subjects, respectively. The percentage of tumor-infiltrating T lymphocytes was significantly higher in breast cancer patients compared to patients with fibroadenoma. Infiltrating helper T lymphocytes were increased in the case of malignant breast lesions, while cytotoxic T lymphocytes disclosed an opposite trend. In addition, our data suggest that the synergistic effect of the presence/activation of NK cells and NKT cells, in line with the data in the literature, determines the dampening of the immune response. Moreover, the lymphocyte-to-monocyte ratio was calculated and was completely altered in patients with breast cancer. Our approach could be a potent prognostic factor to be used in diagnostic/therapeutic purposes for the improvement of breast cancer patients' management.
Identifiants
pubmed: 36010863
pii: cancers14163869
doi: 10.3390/cancers14163869
pmc: PMC9406207
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Ministero della Salute
ID : Ricerca corrente
Références
Front Immunol. 2018 Mar 08;9:470
pubmed: 29568299
NPJ Breast Cancer. 2021 Dec 1;7(1):150
pubmed: 34853355
Front Immunol. 2020 Jun 09;11:1152
pubmed: 32582215
J Clin Oncol. 2009 Apr 10;27(11):1746-52
pubmed: 19255331
Adv Anat Pathol. 2017 Sep;24(5):235-251
pubmed: 28777142
Clin Exp Metastasis. 2013 Dec;30(8):1047-62
pubmed: 23836289
Front Oncol. 2020 Sep 17;10:1399
pubmed: 33042791
Br J Cancer. 2021 Jan;124(2):359-367
pubmed: 32929195
Cancers (Basel). 2021 Aug 03;13(15):
pubmed: 34359821
Nat Rev Cancer. 2020 Aug;20(8):437-454
pubmed: 32581320
Nat Rev Immunol. 2020 Nov;20(11):651-668
pubmed: 32433532
J Clin Oncol. 2009 Dec 10;27(35):5944-51
pubmed: 19858404
JAMA Oncol. 2016 Oct 01;2(10):1354-1360
pubmed: 27355489
Cell Oncol (Dordr). 2016 Jun;39(3):211-28
pubmed: 26769126
Cell Rep. 2014 Mar 13;6(5):779-81
pubmed: 24630040
Cancer Gene Ther. 2021 Feb;28(1-2):5-17
pubmed: 32457487
Ann Oncol. 2015 Feb;26(2):259-71
pubmed: 25214542
J Clin Oncol. 2008 Sep 20;26(27):4410-7
pubmed: 18802153
Clin Breast Cancer. 2021 Feb;21(1):e63-e73
pubmed: 32893093
Front Immunol. 2022 Feb 11;13:794175
pubmed: 35222378
Cancer Control. 2021 Jan-Dec;28:10732748211048612
pubmed: 34620015
J Clin Oncol. 2010 Jan 1;28(1):105-13
pubmed: 19917869
J Immunother Precis Oncol. 2021 Oct 26;5(1):7-9
pubmed: 35663830
Cell. 2022 Mar 31;185(7):1189-1207.e25
pubmed: 35325594
J Hematol Oncol. 2021 Mar 23;14(1):49
pubmed: 33757574
Breast Dis. 2020;39(2):61-69
pubmed: 32310155
Nat Rev Drug Discov. 2020 Mar;19(3):200-218
pubmed: 31907401
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Immunother Cancer. 2016 Oct 18;4:59
pubmed: 27777769
Cancer. 2007 Oct 15;110(8):1677-86
pubmed: 17763371
Cancer Chemother Pharmacol. 2021 Feb;87(2):147-158
pubmed: 33420940
Cell Tissue Bank. 2009 Nov;10(4):301-8
pubmed: 19184530
Immunity. 2016 Nov 15;45(5):1122-1134
pubmed: 27851913
Breast Cancer Res Treat. 2014 Apr;144(3):539-49
pubmed: 24596048
Mod Pathol. 2016 Oct;29(10):1155-64
pubmed: 27363491
Front Immunol. 2014 Nov 24;5:607
pubmed: 25505472
Mod Pathol. 2016 Mar;29(3):249-58
pubmed: 26769139
Proc Natl Acad Sci U S A. 2013 Oct 29;110(44):17945-50
pubmed: 24127572
Mol Cancer. 2020 Aug 6;19(1):120
pubmed: 32762681
Br J Cancer. 1990 Dec;62(6):971-5
pubmed: 2124138
Histopathology. 2017 Aug;71(2):258-268
pubmed: 28326600
Nat Rev Clin Oncol. 2016 Apr;13(4):228-41
pubmed: 26667975
Adv Exp Med Biol. 2020;1224:35-51
pubmed: 32036603
Cytometry B Clin Cytom. 2011 Jul-Aug;80(4):201-11
pubmed: 21674774
Front Immunol. 2018 Feb 27;9:367
pubmed: 29535734
Nat Rev Immunol. 2018 Oct;18(10):635-647
pubmed: 30057419
Genome Biol. 2019 Oct 17;20(1):210
pubmed: 31623682
Breast Cancer Res. 2020 May 14;22(1):47
pubmed: 32408905
Tumori. 2018 Jun;104(3):196-201
pubmed: 28430349
Clin Adv Hematol Oncol. 2016 Nov;14(11):922-933
pubmed: 27930644